Advanced

Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke

Salas Perdomo, Angelica ; Miro, Francesc ; Gallizioli, Mattia ; Brait, Vanessa ; Justizia, Carles ; Meissner, Anja LU ; Urra, Xavier ; Chamorro, Angel and Planas, Anna M. (2019) In Scientific Reports 9. p.1-13
Abstract
Hemorrhagic transformation (HT) is a complication of severe ischemic stroke after revascularization. Patients with low platelet counts do not receive reperfusion therapies due to high risk of HT. The immunomodulatory drug fingolimod attenuated HT after tissue plasminogen activator in a thromboembolic stroke model, but the underlying mechanism is unknown. Fingolimod acts on several sphingosine-1-phosphate (S1P) receptors, prevents lymphocyte trafficking to inflamed tissues, and affects brain and vascular cells. This study aimed to investigate changes in S1P-signaling in response to brain ischemia/reperfusion and the effects of the S1P receptor modulator fingolimod on HT. We studied brain expression of S1P signaling components, S1P... (More)
Hemorrhagic transformation (HT) is a complication of severe ischemic stroke after revascularization. Patients with low platelet counts do not receive reperfusion therapies due to high risk of HT. The immunomodulatory drug fingolimod attenuated HT after tissue plasminogen activator in a thromboembolic stroke model, but the underlying mechanism is unknown. Fingolimod acts on several sphingosine-1-phosphate (S1P) receptors, prevents lymphocyte trafficking to inflamed tissues, and affects brain and vascular cells. This study aimed to investigate changes in S1P-signaling in response to brain ischemia/reperfusion and the effects of the S1P receptor modulator fingolimod on HT. We studied brain expression of S1P signaling components, S1P concentration, and immune cell infiltration after ischemia/reperfusion in mice. We administered fingolimod after ischemia to wild-type mice, lymphocyte-deficient Rag2−/− mice, and mice with low platelet counts. Ischemia increased S1P-generating enzyme SphK1 mRNA, S1P concentration, and S1P receptor-1 (S1P1)+ T-cells in the brain. Fingolimod prevented lymphocyte infiltration, and attenuated the severity of HT in Rag2−/− mice but it was ineffective under thrombocytopenia. Fingolimod prevented β-catenin degradation but not Evans blue extravasation. Ischemia/reperfusion upregulates brain S1P signaling pathway, and fingolimod exerts local effects that attenuate HT. Although fingolimod seems to act on the brain tissue, it did not prevent blood-brain barrier leakage. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scientific Reports
volume
9
article number
8309
pages
1 - 13
publisher
Nature Publishing Group
external identifiers
  • scopus:85066617632
  • pmid:31165772
ISSN
2045-2322
DOI
10.1038/s41598-019-44845-5
language
English
LU publication?
yes
id
f955c153-67be-4480-ad2f-3d25b41e88e3
date added to LUP
2019-06-09 11:29:29
date last changed
2020-01-22 07:39:20
@article{f955c153-67be-4480-ad2f-3d25b41e88e3,
  abstract     = {Hemorrhagic transformation (HT) is a complication of severe ischemic stroke after revascularization. Patients with low platelet counts do not receive reperfusion therapies due to high risk of HT. The immunomodulatory drug fingolimod attenuated HT after tissue plasminogen activator in a thromboembolic stroke model, but the underlying mechanism is unknown. Fingolimod acts on several sphingosine-1-phosphate (S1P) receptors, prevents lymphocyte trafficking to inflamed tissues, and affects brain and vascular cells. This study aimed to investigate changes in S1P-signaling in response to brain ischemia/reperfusion and the effects of the S1P receptor modulator fingolimod on HT. We studied brain expression of S1P signaling components, S1P concentration, and immune cell infiltration after ischemia/reperfusion in mice. We administered fingolimod after ischemia to wild-type mice, lymphocyte-deficient Rag2−/− mice, and mice with low platelet counts. Ischemia increased S1P-generating enzyme SphK1 mRNA, S1P concentration, and S1P receptor-1 (S1P1)+ T-cells in the brain. Fingolimod prevented lymphocyte infiltration, and attenuated the severity of HT in Rag2−/− mice but it was ineffective under thrombocytopenia. Fingolimod prevented β-catenin degradation but not Evans blue extravasation. Ischemia/reperfusion upregulates brain S1P signaling pathway, and fingolimod exerts local effects that attenuate HT. Although fingolimod seems to act on the brain tissue, it did not prevent blood-brain barrier leakage.},
  author       = {Salas Perdomo, Angelica and Miro, Francesc and Gallizioli, Mattia and Brait, Vanessa and Justizia, Carles and Meissner, Anja and Urra, Xavier and Chamorro, Angel and Planas, Anna M.},
  issn         = {2045-2322},
  language     = {eng},
  pages        = {1--13},
  publisher    = {Nature Publishing Group},
  series       = {Scientific Reports},
  title        = {Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke},
  url          = {http://dx.doi.org/10.1038/s41598-019-44845-5},
  doi          = {10.1038/s41598-019-44845-5},
  volume       = {9},
  year         = {2019},
}